DNA vaccines induce partial protection against Leishmania mexicana

Vaccine

Volumn 21, Issue 17-18, 2003, Pages 2161-2168

  Dumonteil, Eric ^a   Jesus, Ramirez Sierra Maria ^a   Javier, Escobedo Ortegon ^a   Del Rosario, García Miss Maria ^a  

^a UNIVERSIDAD AUTÓNOMA DE YUCATÁN   (Mexico)

Author keywords

DNA vaccines; Leishmania mexicana; Partial protection

Indexed keywords

ANTIBODY; BACTERIAL ANTIGEN; DNA VACCINE; PLASMID DNA; PROTEIN CPB; PROTEIN GP46; PROTEIN GP63; PROTEIN LACK; UNCLASSIFIED DRUG; VIRUS VECTOR;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG EFFICACY; DRUG SCREENING; FEMALE; HUMORAL IMMUNITY; IMMUNOGENICITY; LEISHMANIA MEXICANA; LEISHMANIASIS; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0037449085     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00769-7     Document Type: Article

References (41)

1. Dumonteil E, McMahon-Pratt D, Price V. Report on the fourth TDR/IDRI meeting on second generation vaccines against leishmaniasis. Meeting Report, WHO/TDR. 2002.
2. Armijos R.X., Weigel M.M., Aviles H., Maldonado R., Racines J. Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up. J. Infect. Dis. 177:1998;1352-1357.
3. Sharifi I., FeKri A.R., Aflatonian M.R.et al. Ramdomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet. 351:1998;1540-1543.
4. Louis J., Himmelrich H., Parra-Lopez C., Tacchini-Cottier F., Launois P. Regulation of protective immunity against Leishmania major in mice. Curr. Opin. Immunol. 10:1998;459-464.
5. Handman E., Symons F.M., Baldwin T.M., Curtis J.M., Scheerlinck J.P. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a Th1 type of immune response. Infect. Immun. 63:1995;4261-4267.
6. Xu D., McSorley S.J., Chatfield S.N., Dougan G., Liew F.Y. Protection against Leishmania major infection in genetically susceptible BALB/c mice by gp63 delivered orally in attenuated Salmonella typhimurium (AroA-, AroD-). Immunology. 85:1995;1-7.
7. Sjolander A., Baldwin T.M., Curtis J.M., Bengtsson K.L., Handman E. Vaccination with recombinant parasite surface antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection. Vaccine. 16:1998;2077-2084.
8. Rafati S., Baba A.A., Bakhshayesh M., Vafa M. Vaccination of BALB/c mice with Leishmania major amastigote-specific cysteine proteinase. Clin. Exp. Immunol. 120:2000;134-138.
9. Papadopoulou G., Karagouni E., Dotsika E. ISCOMs vaccine against experimental leishmaniasis. Vaccine. 16:1998;885-892.
10. McMahon-Pratt D., Rodriguez D., Rodriguez J.R.et al. Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection. Infect. Immun. 61:1993;3351-3359.
11. Lai W.C., Bennett M. DNA vaccines. Crit. Rev. Immunol. 18:1998;449-484.
12. Xu D., Liew F.Y. Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of L. major. Immunology. 84:1995;173-176.
13. Sjolander A., Baldwin T.M., Curtis J.M., Handman E. Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis. J. Immunol. 160:1998;3949-3957.
14. Walker P.S., Scharton-Kersten T., Rowton E.D.et al. Genetic immunization with glycoprotein 63 cDNA results in a helper T-cell type 1 immune response and protection in a murine model of leishmaniasis. Hum. Gene. Ther. 9:1998;1899-1907.
15. Gurunathan S., Prussin C., Sacks D.L., Seder R.A. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat. Med. 4:1998;1409-1415.
16. + T-cells. J. Immunol. 165:2000;915-924.
17. Alexander J., Coombs G.H., Mottram J.C. Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response. J. Immunol. 161:1998;6794-6801.
18. Alexander J., Phillips R.S. Leishmania tropica and Leishmania mexicana: cross-immunity in mice. Exp. Parasitol. 45:1978;93-100.
19. Aebischer T., Wolfram M., Patzer S.I., Ilg T., Wiese M., Overath P. Subunit vaccination of mice against new world cutaneous leishmaniasis: comparison of three proteins expressed in amastigotes and six adjuvants. Infect. Immun. 68:2000;1328-1336.
20. Gonzalez C.R., Noriega F.R., Huerta S.et al. Immunogenicity of a Salmonella typhi CVD 908 candidate vaccine strain expressing the major surface protein gp63 of Leishmania mexicana mexicana. Vaccine. 16:1998;1043-1052.
21. Lezama-Davila C.M. Vaccination of different strains of mice against cutaneous leishmaniasis: usefulness of membrane antigens encapsulated into liposomes by intraperitoneal and subcutaneous administration. Arch. Med. Res. 28:1997;47-53.
22. Lezama-Davila C.M. Vaccination of C57BL/10 mice against cutaneous leishmaniasis. Use of purified gp63 encapsulated into niosomes surfactants vesicles: a novel approach. Mem. Inst. Oswaldo. Cruz. 94:1999;67-70.
23. Torrentera F.A., Glaichenhaus N., Laman J.D., Carlier Y. T-cell responses to immunodominant LACK antigen do not play a critical role in determining susceptibility of BALB/c mice to Leishmania mexicana. Infect. Immun. 69:2001;617-621.
24. Dumonteil E., Andrade-Narvaez F., Escobedo-Ortegon J.et al. Comparative study of DNA vaccines encoding various antigens against Leishmania mexicana. Dev. Biol. Stand. 104:2000;135-141.
25. Lima H.C., Bleyenberg J.A., Titus R.G. A simple method for quantifying Leishmania in tissues of infected animals. Parasitol. Today. 13:1997;80-82.
26. Seder R.A., Hill A.V.S. Vaccine against intracellular infections requiring cellular immunity. Nature. 406:2000;793-798.
27. Leclerc C., Deriaud E., Rojas M., Whalen R.G. The preferential induction of a Th1 immune response by DNA-based immunization is mediated by the immunostimulatory effect of plasmid DNA. Cell Immunol. 179:1997;97-106.
28. Krieg A.M., Yi A.K., Schorr J., Davis H.L. The role of CpG dinucleotides in DNA vaccines. Trends. Microbiol. 6:1998;23-27.
29. Klinman D.M., Ishii K.J., Verthelyi D. CpG DNA augments the immunogenicity of plasmid DNA vaccines. Curr. Top Microbiol. Immunol. 247:2000;131-142.
30. Guerbouj S., Victoir K., Guizani I.et al. Gp63 gene polymorphism and population structure of Leishmania donovani complex: influence of the host selection pressure. Parasitology. 122 Pt 1:2001;25-35.
31. Guerbouj S., Guizani I., Victoir K., Le Ray D., Dujardin J.C. Parasite candidate vaccines: a warning from polymorphic Leishmania populations. Parasitol. Today. 16:2000;265.
32. Gutierrez A., Vicini J., Patarroyo M.E., Murillo L.A., Patarroyo M.A. Plasmodium vivax: polymorphism in the merozoite surface protein 1 gene from wild Colombian isolates. Exp. Parasitol. 95:2000;215-219.
33. Gurunathan S., Sacks D.L., Brown D.R.et al. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J. Exp. Med. 186:1997;1137-1147.
34. Lemos de Souza V.V., Ascencao Souza J., Correia Silva T.M., Sampaio Tavares Veras P., Rodrigues de-Freitas L.A. Different Leishmania species determine distinct profiles of immune and histopathological responses in CBA mice. Microbes Infect. 2:2000;1807-1815.
35. Guevara-Mendoza O., Une C., Franceschi Carreira P., Orn A. Experimental infection of Balb/c mice with Leishmania panamensis and Leishmania mexicana: induction of early IFN-gamma but not IL-4 is associated with the development of cutaneous lesions. Scand. J. Immunol. 46:1997;35-40.
36. Rafati S., Salmanian A.F., Taheri T., Vafa M., Fasel N. A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major. Vaccine. 19:2001;3369-3375.
37. Campos-Neto A., Webb J.R., Greeson K., Coler R.N., Skeiky Y.A., Reed S.G. Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice. Infect. Immun. 70:2002;2828-2836.
38. Morris S., Kelley C., Howard A., Li Z., Collins F. The immunogenicity of single and combination DNA vaccines against tuberculosis. Vaccine. 18:2000;2155-2163.
39. Braun R., Babiuk L.A., van Drunen Littel-van den H. Compatibility of plasmids expressing different antigens in a single DNA vaccine formulation. J. Gen. Virol. 79:1998;2965-2970.
40. Grifantini R., Finco O., Bartolini E.et al. Multi-plasmid DNA vaccination avoids antigenic competition and enhances immunogenicity of a poorly immunogenic plasmid. Eur. J. Immunol. 28:1998;1225-1232.
41. Zhang Y., Taylor M.G., HJohansen M.V., Bickle Q.D. Vaccination of mice with a cocktail DNA vaccine induces a Th1-type immune response and partial protection against Schistosoma japonicum infection. Vaccine. 20:2001;724-730.